INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV

Overview

This is an unblinded cluster-randomized study to evaluate the effectiveness of two strategies for scripting/dispensing of antiretroviral therapy (ART) on retention, virologic suppression, and cost compared to the standard of care. The study will be conducted in Malawi and Zambia among approximately 8,200 HIV-1-infected adults (18 years or older) who are stable on ART. Clusters will be randomized to one of three study arms: (1) standard of care (SOC) ART scripting (varies by country, region, clinic, and/or provider), (2) three-month ART scripting, and (3) six-month ART scripting. 30 clusters will be selected for the study, 15 in Malawi and 15 in Zambia, and will be randomized to a study arm.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Health Services Research
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 30, 2019

Detailed Description

This study will be conducted among approximately 8,200 HIV-infected individuals age 18 years or older who are stable on antiretroviral therapy (ART) in 30 clusters in Malawi and Zambia. Individuals will be screened at routine clinic visits and enrolled if they meet inclusion criteria. Enrolled individuals will receive standard of care at their site with the exception of their ART dispensing interval based on the assigned randomization. Outcomes will be assessed after 12 months, but all participants will be under observational follow-up for 36 months, with annual re-assessment of retention, virologic suppression, and cost-effectiveness.

There will be no contact with study participants during the period of follow-up.

Endpoints will be determined by chart review after the primary endpoint is reached (12 months). Endpoint data collection will include:

1. Retention in care on strategy

2. Suppressed viral load of <1,000 copies done as part of standard of care viral load monitoring

In a subset of participants in Malawi (n=1,500), we will perform a review of participants' health passports, a record of patient clinic visits, general health information, and medications that is possessed by patients in Malawi, after the 12-month endpoint has been completed. Data will be collected on interim clinic visits, such as reason for visit/services received (sick, family planning, non-communicable disease treatment), frequency of visits, and location of clinic services.

In a subset of participants (~240), we will perform a post intervention study visit after the 12-month endpoint is completed. Qualitative interviews will be performed with a subset of participants and will focus on patient experience with assigned dispensing interval, including challenges/barriers and facilitators towards adherence and retention. Focused questions around endpoints (if default, reasons; if virologic failure, reasons including adherence) will also be addressed in the post-intervention visit.

Interventions

  • Other: Three-month ART dispensing
    • Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
  • Other: Six-month ART dispensing
    • Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.

Arms, Groups and Cohorts

  • No Intervention: Standard of care ART dispensing
    • The standard of care arm will allow ART dispensing based on usual practice at the clinic. Standard of care is anticipated to have variability in how ART is dispensed, although the approach should be consistent with applicable country guidelines at the time of study.
  • Experimental: Three-month ART dispensing
    • Providers at facilities randomized to three-month ART dispensing will be expected to provide all enrolled patients with a 90-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.
  • Experimental: Six-month ART dispensing
    • Providers at facilities randomized to six-month ART dispensing will be expected to provide all enrolled patients with a 180-day supply of ART and associated HIV medications (cotrimoxazole and isoniazid if part of country guidelines). All other aspects of care will be as per standard of care for the enrolling clinic.

Clinical Trial Outcome Measures

Primary Measures

  • Retention in care at 12 months
    • Time Frame: 12 months
    • The primary outcome to be studied is whether scripting/dispensing of ART for intervals of six months is non-inferior to three months with respect to retention in care.

Secondary Measures

  • Virologic suppression at 12 months
    • Time Frame: 12 months
    • The secondary outcome to be studied is whether scripting/dispensing of ART for intervals of six months is non-inferior to three months with respect to a viral load outcome of <1,000 copies/ml (undetectable) at 12 months.
  • Cost-effectiveness of ART dispensing
    • Time Frame: 12 months
    • The secondary outcome to be studied is the cost-effectiveness of scripting/dispensing of ART for intervals of six months compared to three months and SOC. Cost-effectiveness will be estimated as the average cost per successful outcome (patient retained at 12 months).

Participating in This Clinical Trial

Inclusion Criteria

  • At least 18 years of age.
  • Willing and able to provide written informed consent for participation in this study.
  • Confirmed HIV-1 infection based on country standard of care for testing.
  • On antiretroviral treatment (ART) for at least six months.
  • On a first-line ART regimen as defined by country-specific guidelines.
  • No drug toxicity/tolerability issues with ART regimen within the prior six months.
  • No period of more than one month without ART medication possession within the last six months.
  • No active opportunistic infection suspected (including tuberculosis) and not treated for an opportunistic infection in the last 30 days.
  • No active comorbidity (including hypertension) and not treated for a comorbidity in the last 30 days.
  • No viral load of more than 1000 copies/ml (using standard assay) within the last six months.
  • Not currently pregnant.
  • At least six months postpartum if recently delivered a baby.
  • Not currently breastfeeding or planning to breastfeed.

Exclusion Criteria

  • Under 18 years of age.
  • Viral load of 1000 copies/ml or greater (using standard assay) within the last six months.
  • On alternative first-line or second-line ART regimen.
  • One month or more without medication possession within the last six months.
  • Experienced an ART toxicity/tolerability issue within the last six months.
  • Currently receiving treatment for tuberculosis or receiving treatment for any other opportunistic infection or comorbidity (including hypertension).
  • Pregnant or less than six months postpartum.
  • Women who are breastfeeding.
  • Unwilling or unable to provide informed consent.
  • Previously enrolled in the study.
  • Currently enrolled in any other research study at the site that involves adherence/retention or alters delivery of HIV care.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of California, Los Angeles
  • Collaborator
    • Boston University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Risa Hoffman, MD, MPH, Associate Clinical Professor – University of California, Los Angeles
  • Overall Official(s)
    • Risa M Hoffman, MD, MPH, Principal Investigator, University of California, Los Angeles

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.